contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      viewerIsFollowing
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
      tags {
        viewerIsFollowing
        id
      }
    }
    ... on Webcast {
      liveTime
      tags {
        viewerIsFollowing
        id
      }
    }
    slug
    ... on CompanyReport {
      tags {
        viewerIsFollowing
        id
      }
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-orexos-q1-2025-interim-report

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Orexo

Uppsala, Sweden – April 25, 2025 – As previously communicated Orexo will announce the Interim Report for the first quarter of 2025 on May 6 at 8 am CEST.The same day at 2 pm CEST, analysts, ...

<div class="mfn-body"><p>Uppsala, Sweden – April 25, 2025 – As previously communicated Orexo will announce the Interim Report for the first quarter of 2025 on May 6 at 8 am CEST.</p><p>The same day at 2 pm CEST, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&amp;A.</p><p>To attend via teleconference where you can ask questions verbally use this link:&nbsp; <br><a rel="noopener" href="https://events.inderes.com/orexo/q1-report-2025/dial-in">https://events.inderes.com/orexo/q1-report-2025/dial-in</a><br>When registered you will be provided phone numbers and a conference ID to access the conference.<br><br>To attend via webcast:<br><a rel="noopener" href="https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Forexo.events.inderes.com%2Fq1-report-2025&amp;data=05%7C02%7CLena.Wange%40orexo.com%7C1622e52aec5a4e448acf08dd7674d609%7Cc2e2c5518fbf4c22b4b3101af7212583%7C1%7C0%7C638796966396596037%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=5r%2FHPrN1j7MRp45FIUgKxIn6wQAULdfa0VE6JrUVb8c%3D&amp;reserved=0">https://orexo.events.inderes.com/q1-report-2025</a></p><p>Prior to the event the presentation material will be available on the website under Investors/Report Archive</p></div><div class="mfn-footer mfn-contacts mfn-2baf0980f754"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Orexo AB (publ.)<br>Lena Wange, IR &amp; Communications Director<br>Tel: +46 (0) 18 780 88 00<br>Email: <a rel="noopener" href="mailto:ir@orexo.com">ir@orexo.com</a></p></div><div class="mfn-footer mfn-about mfn-4dfc8ccab0b6"><p><strong class="mfn-heading-1">About Orexo</strong><br>Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX market (ORXOY) in the US.</p><p>For more information about Orexo please visit <a rel="noopener" href="http://www.orexo.com.">www.orexo.com</a>. You can also follow Orexo on X, LinkedIn, and YouTube.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/af1f1711-f800-4857-832a-e9bef3801fc5/invitation-to-presentation-of-orexo-s-q1-2025-interim-report.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Orexo´s Q1 2025 Interim Report</a></p></div>